REFERENCES
2. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
4. Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 2008;1781:513-8.
5. Yung YC, Stoddard NC, Chun J. LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res 2014;55:1192-214.
6. Bektas M, Payne SG, Liu H, Goparaju S, Milstien S, Spiegel S. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J Cell Biol 2005;169:801-11.
7. Tomsig JL, Snyder AH, Berdyshev EV, et al. Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochem J 2009;419:611-8.
8. Saba JD. Lysophospholipids in development: Miles apart and edging in. J Cell Biochem 2004;92:967-92.
9. Pagès C, Simon M, Valet P, Saulnier-blache JS. Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat 2001;64:1-10.
10. van Meeteren LA, Ruurs P, Stortelers C, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 2006;26:5015-22.
11. Stefan C, Jansen S, Bollen M. NPP-type ectophosphodiesterases: unity in diversity. Trends Biochem Sci 2005;30:542-50.
12. Nikitopoulou I, Oikonomou N, Karouzakis E, et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med 2012;209:925-33.
13. Dusaulcy R, Rancoule C, Grès S, et al. Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J Lipid Res 2011;52:1247-55.
14. Kanda H, Newton R, Klein R, Morita Y, Gunn MD, Rosen SD. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat Immunol 2008;9:415-23.
15. van Meeteren LA, Ruurs P, Christodoulou E, et al. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem 2005;280:21155-61.
16. David M, Machuca-Gayet I, Kikuta J, et al. Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity. J Biol Chem 2014;289:6551-64.
17. Alioli CA, Demesmay L, Laurencin-Dalacieux S, et al. Expression of the type 1 lysophosphatidic acid receptor in osteoblastic cell lineage controls both bone mineralization and osteocyte specification. Biochim Biophys Acta Mol Cell Biol Lipids 2020;1865:158715.
18. Pasternack SM, von Kügelgen I, Al Aboud K, et al. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet 2008;40:329-34.
19. Boucharaba A, Serre CM, Grès S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004;114:1714-25.
20. Blackburn J, Mansell JP. The emerging role of lysophosphatidic acid (LPA) in skeletal biology. Bone 2012;50:756-62.
21. Gennero I, Laurencin-Dalicieux S, Conte-Auriol F, et al. Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass. Bone 2011;49:395-403.
22. Liu YB, Kharode Y, Bodine PV, Yaworsky PJ, Robinson JA, Billiard J. LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4. J Cell Biochem 2010;109:794-800.
23. Lapierre DM, Tanabe N, Pereverzev A, et al. Lysophosphatidic acid signals through multiple receptors in osteoclasts to elevate cytosolic calcium concentration, evoke retraction, and promote cell survival. J Biol Chem 2010;285:25792-801.
24. Karagiosis SA, Karin NJ. Lysophosphatidic acid induces osteocyte dendrite outgrowth. Biochem Biophys Res Commun 2007;357:194-9.
25. McMichael BK, Meyer SM, Lee BS. c-Src-mediated phosphorylation of thyroid hormone receptor-interacting protein 6 (TRIP6) promotes osteoclast sealing zone formation. J Biol Chem 2010;285:26641-51.
26. David M, Wannecq E, Descotes F, et al. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One 2010;5:e9741.
27. Miyabe Y, Miyabe C, Iwai Y, et al. Necessity of lysophosphatidic acid receptor 1 for development of arthritis. Arthritis Rheum 2013;65:2037-47.
28. Flammier S, Peyruchaud O, Bourguillault F, et al. Osteoclast-derived autotaxin, a distinguishing factor for inflammatory bone loss. Arthritis Rheumatol 2019;71:1801-11.
29. Leblanc R, Lee SC, David M, et al. Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone. Blood 2014;124:3141-50.
30. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992;267:2524-9.
31. Lin ME, Herr DR, Chun J. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 2010;91:130-8.
32. Choi JW, Herr DR, Noguchi K, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 2010;50:157-86.
33. Sedláková I, Vávrová J, Tošner J, Hanousek L. Lysophosphatidic acid (LPA)-a perspective marker in ovarian cancer. Tumour Biol 2011;32:311-6.
34. Ikeda H, Enooku K, Ohkawa R, Koike K, Yatomi Y. Plasma lysophosphatidic acid levels and hepatocellular carcinoma. Hepatology 2013;57:417-8.
35. Xu Y, Fang XJ, Casey G, Mills GB. Lysophospholipids activate ovarian and breast cancer cells. Biochem J 1995;309:933-40.
36. Lin CI, Chen CN, Huang MT, et al. Lysophosphatidic acid upregulates vascular endothelial growth factor-C and tube formation in human endothelial cells through LPA(1/3), COX-2, and NF-kappaB activation- and EGFR transactivation-dependent mechanisms. Cell Signal 2008;20:1804-14.
37. Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 2012;72:1909-14.
38. Bellahcène A, Bachelier R, Detry C, Lidereau R, Clézardin P, Castronovo V. Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat 2007;101:135-48.
39. Wu X, Ma Y, Chen H, et al. Lysophosphatidic acid induces interleukin-6 and CXCL15 secretion from MLO-Y4 cells through activation of the LPA1 receptor and PKCθ signaling pathway. Int Immunopharmacol 2019;74:105664.
40. Aki Y, Kondo A, Nakamura H, Togari A. Lysophosphatidic acid-stimulated interleukin-6 and -8 synthesis through LPA1 receptors on human osteoblasts. Arch Oral Biol 2008;53:207-13.
41. Peyruchaud O, Winding B, Pécheur I, Serre CM, Delmas P, Clézardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001;16:2027-34.
42. Masuda A, Nakamura K, Izutsu K, et al. Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br J Haematol 2008;143:60-70.
43. Nakai Y, Ikeda H, Nakamura K, et al. Specific increase in serum autotaxin activity in patients with pancreatic cancer. Clin Biochem 2011;44:576-81.
44. Zhang G, Zhao Z, Xu S, Ni L, Wang X. Expression of autotaxin mRNA in human hepatocellular carcinoma. Chin Med J (Engl) 1999;112:330-2.
45. Benesch MG, Tang X, Dewald J, et al. Tumor-induced inflammation in mammary adipose tissue stimulates a vicious cycle of autotaxin expression and breast cancer progression. FASEB J 2015;29:3990-4000.
46. Benesch MG, Ko YM, Tang X, et al. Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer. Endocr Relat Cancer 2015;22:593-607.
47. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-9.
48. Aielli F, Ponzetti M, Rucci N. Bone metastasis pain, from the bench to the bedside. Int J Mol Sci 2019;20:280.
49. Yoneda T, Hata K, Nakanishi M, et al. Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone 2011;48:100-5.
50. Zhao J, Pan HL, Li TT, Zhang YQ, Wei JY, Zhao ZQ. The sensitization of peripheral C-fibers to lysophosphatidic acid in bone cancer pain. Life Sci 2010;87:120-5.
51. Pan HL, Zhang YQ, Zhao ZQ. Involvement of lysophosphatidic acid in bone cancer pain by potentiation of TRPV1 via PKCε pathway in dorsal root ganglion neurons. Mol Pain 2010;6:85.
52. Wu JX, Yuan XM, Wang Q, Wei W, Xu MY. Rho/ROCK acts downstream of lysophosphatidic acid receptor 1 in modulating P2X3 receptor-mediated bone cancer pain in rats. Mol Pain 2016;12:174480691664492.
54. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008;9:139-50.
55. Kitatani K, Idkowiak-Baldys J, Hannun YA. The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal 2008;20:1010-8.
56. Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol 2018;19:175-91.
57. Ramos-Perez WD, Fang V, Escalante-Alcalde D, Cammer M, Schwab SR. A map of the distribution of sphingosine 1-phosphate in the spleen. Nat Immunol 2015;16:1245-52.
58. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 2005;309:1735-9.
59. Yanagida K, Hla T. Vascular and immunobiology of the circulatory sphingosine 1-phosphate gradient. Annu Rev Physiol 2017;79:67-91.
60. Sartawi Z, Schipani E, Ryan KB, Waeber C. Sphingosine 1-phosphate (S1P) signalling: Role in bone biology and potential therapeutic target for bone repair. Pharmacol Res 2017;125:232-45.
61. Vu TM, Ishizu AN, Foo JC, et al. Mfsd2b is essential for the sphingosine-1-phosphate export in erythrocytes and platelets. Nature 2017;550:524-8.
62. Proia RL, Hla T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest 2015;125:1379-87.
63. Thuy AV, Reimann CM, Hemdan NY, Gräler MH. Sphingosine 1-phosphate in blood: function, metabolism, and fate. Cell Physiol Biochem 2014;34:158-71.
64. Christoffersen C, Obinata H, Kumaraswamy SB, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A 2011;108:9613-8.
65. Obinata H, Kuo A, Wada Y, et al. Identification of ApoA4 as a sphingosine 1-phosphate chaperone in ApoM- and albumin-deficient mice. J Lipid Res 2019;60:1912-21.
66. Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 2012;30:69-94.
67. Hla T, Venkataraman K, Michaud J. The vascular S1P gradient-cellular sources and biological significance. Biochim Biophys Acta 2008;1781:477-82.
68. Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev 2010;62:579-87.
69. Rosen H, Stevens RC, Hanson M, Roberts E, Oldstone MB. Sphingosine-1-phosphate and its receptors: structure, signaling, and influence. Annu Rev Biochem 2013;82:637-62.
70. Ishii M, Kikuta J. Sphingosine-1-phosphate signaling controlling osteoclasts and bone homeostasis. Biochim Biophys Acta 2013;1831:223-7.
71. Keller J, Catala-Lehnen P, Huebner AK, et al. Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts. Nat Commun 2014;5:5215.
72. Ryu J, Kim HJ, Chang EJ, Huang H, Banno Y, Kim HH. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J 2006;25:5840-51.
73. Ishii M, Kikuta J, Shimazu Y, Meier-Schellersheim M, Germain RN. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J Exp Med 2010;207:2793-8.
74. Ishii T, Shimazu Y, Nishiyama I, Kikuta J, Ishii M. The role of sphingosine 1-phosphate in migration of osteoclast precursors; an application of intravital two-photon microscopy. Mol Cells 2011;31:399-403.
75. Weske S, Vaidya M, Reese A, et al. Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss. Nat Med 2018;24:667-78.
76. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A 2008;105:20764-9.
77. Lotinun S, Kiviranta R, Matsubara T, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest 2013;123:666-81.
78. Bae SJ, Lee SH, Ahn SH, Kim HM, Kim BJ, Koh JM. The circulating sphingosine-1-phosphate level predicts incident fracture in postmenopausal women: a 3.5-year follow-up observation study. Osteoporos Int 2016;27:2533-41.
79. Weske S, Vaidya M, von Wnuck Lipinski K, et al. Agonist-induced activation of the S1P receptor 2 constitutes a novel osteoanabolic therapy for the treatment of osteoporosis in mice. Bone 2019;125:1-7.
80. Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer 2018;18:33-50.
81. Oshi M, Newman S, Tokumaru Y, et al. Intra-tumoral angiogenesis is associated with inflammation, immune reaction and metastatic recurrence in breast cancer. Int J Mol Sci 2020;21:6708.
82. Kim EY, Choi B, Kim JE, Park SO, Kim SM, Chang EJ. Interleukin-22 mediates the chemotactic migration of breast cancer cells and macrophage infiltration of the bone microenvironment by potentiating S1P/SIPR signaling. Cells 2020;9:131.
83. Filipenko I, Schwalm S, Reali L, et al. Upregulation of the S1P(3) receptor in metastatic breast cancer cells increases migration and invasion by induction of PGE(2) and EP(2)/EP(4) activation. Biochimica et biophysica acta 2016;1861:1840-51.
84. Stayrook KR, Mack JK, Cerabona D, et al. TGFβ-mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis. Bonekey Rep 2015;4:719.
86. Bouquerel P, Gstalder C, Müller D, et al. Essential role for SphK1/S1P signaling to regulate hypoxia-inducible factor 2α expression and activity in cancer. Oncogenesis 2016;5:e209.
87. Gstalder C, Ader I, Cuvillier O. FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model. Mol Cancer Ther 2016;15:2465-74.
88. Xu Y, Dong B, Wang J, Zhang J, Xue W, Huang Y. Sphingosine kinase 1 overexpression contributes to sunitinib resistance in clear cell renal cell carcinoma. Oncoimmunology 2018;7:e1502130.
89. Zhang L, Wang X, Bullock AJ, et al. Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clin Cancer Res 2015;21:1925-34.
90. Pal SK, Drabkin HA, Reeves JA, et al. A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma. Cancer 2017;123:576-82.
91. Schneider G, Sellers ZP, Bujko K, Kakar SS, Kucia M, Ratajczak MZ. Novel pleiotropic effects of bioactive phospholipids in human lung cancer metastasis. Oncotarget 2017;8:58247-63.
92. Ader I, Gstalder C, Bouquerel P, et al. Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer. Oncotarget 2015;6:13803-21.
93. Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B, Cuvillier O. First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer. Mol Cancer Ther 2012;11:1841-51.
94. Malavaud B, Pchejetski D, Mazerolles C, et al. Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur J Cancer 2010;46:3417-24.
95. Brizuela L, Martin C, Jeannot P, et al. Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells. Mol Oncol 2014;8:1181-95.
96. Bao Y, Guo Y, Zhang C, Fan F, Yang W. Sphingosine Kinase 1 and Sphingosine-1-Phosphate Signaling in Colorectal Cancer. Int J Mol Sci 2017;18:2109.
97. Grbčić P, Sedić M. Sphingosine 1-Phosphate Signaling and Metabolism in Chemoprevention and Chemoresistance in Colon Cancer. Molecules 2020;25:2436.
98. Liu SQ, Xu CY, Wu WH, et al. Sphingosine kinase 1 promotes the metastasis of colorectal cancer by inducing the epithelialmesenchymal transition mediated by the FAK/AKT/MMPs axis. Int J Oncol 2019;54:41-52.
99. Bae GE, DO SI, Kim K, Park JH, Cho S, Kim HS. Increased Sphingosine Kinase 1 Expression Predicts Distant Metastasis and Poor Outcome in Patients With Colorectal Cancer. Anticancer Res 2019;39:663-70.
100. Schwiebs A, Herrero San Juan M, Schmidt KG, et al. Cancer-induced inflammation and inflammation-induced cancer in colon: a role for S1P lyase. Oncogene 2019;38:4788-803.
101. Gu X, Jiang Y, Xue W, et al. SPNS2 promotes the malignancy of colorectal cancer cells via regulating Akt and ERK pathway. Clin Exp Pharmacol Physiol 2019;46:861-71.
102. Zhang YH, Cui SX, Wan SB, Wu SH, Qu XJ. Increased S1P induces S1PR2 internalization to blunt the sensitivity of colorectal cancer to 5-fluorouracil via promoting intracellular uracil generation. Acta Pharmacol Sin 2021;42:460-9.
103. Olesch C, Sirait-Fischer E, Berkefeld M, et al. S1PR4 ablation reduces tumor growth and improves chemotherapy via CD8+ T cell expansion. J Clin Invest 2020;130:5461-76.
104. Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 1999;128:1121-32.
107. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997;387:620-4.
108. Bäck M, Powell WS, Dahlén SE, et al. Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br J Pharmacol 2014;171:3551-74.
109. Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999;399:789-93.
110. Heise CE, O'Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000;275:30531-6.
111. Pilbeam CC, Harrison JR, Raisz LG. Chapter 54 - Prostaglandins and Bone Metabolism. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of Bone Biology (Second Edition). San Diego: Academic Press; 2002. p. 979-94.
112. Hikiji H, Ishii S, Yokomizo T, Takato T, Shimizu T. A distinctive role of the leukotriene B4 receptor BLT1 in osteoclastic activity during bone loss. Proc Natl Acad Sci U S A 2009;106:21294-9.
113. Miyaura C, Inada M, Suzawa T, et al. Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. J Biol Chem 2000;275:19819-23.
114. Sakuma Y, Tanaka K, Suda M, et al. Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J Bone Miner Res 2000;15:218-27.
115. Wani MR, Fuller K, Kim NS, Choi Y, Chambers T. Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Endocrinology 1999;140:1927-35.
116. Kobayashi Y, Take I, Yamashita T, et al. Prostaglandin E2 receptors EP2 and EP4 are downregulated during differentiation of mouse osteoclasts from their precursors. J Biol Chem 2005;280:24035-42.
117. Yoshida K, Oida H, Kobayashi T, et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Natl Acad Sci U S A 2002;99:4580-5.
118. Alander CB, Raisz LG. Effects of selective prostaglandins E2 receptor agonists on cultured calvarial murine osteoblastic cells. Prostaglandins Other Lipid Mediat 2006;81:178-83.
119. Forwood MR. Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res 1996;11:1688-93.
120. Bonewald LF, Flynn M, Qiao M, Dallas MR, Mundy GR, Boyce BF. Mice lacking 5-lipoxygenase have increased cortical bone thickness. Adv Exp Med Biol 1997;433:299-302.
121. Le P, Kawai M, Bornstein S, DeMambro VE, Horowitz MC, Rosen CJ. A high-fat diet induces bone loss in mice lacking the Alox5 gene. Endocrinology 2012;153:6-16.
122. Moura AP, Taddei SR, Queiroz-Junior CM, et al. The relevance of leukotrienes for bone resorption induced by mechanical loading. Bone 2014;69:133-8.
123. Madeira MFM, Queiroz-Junior CM, Corrêa JD, et al. The role of 5-lipoxygenase in Aggregatibacter actinomycetemcomitans-induced alveolar bone loss. J Clin Periodontol 2017;44:793-802.
124. Zheng LX, Li KX, Hong FF, Yang SL. Pain and bone damage in rheumatoid arthritis: role of leukotriene B4. Clinical and experimental rheumatology. 2019;37:872-8.
125. Lee JM, Park H, Noh AL, et al. 5-Lipoxygenase mediates RANKL-induced osteoclast formation via the cysteinyl leukotriene receptor 1. J Immunol 2012;189:5284-92.
126. Kang JH, Lim H, Lee DS, Yim M. Montelukast inhibits RANKLinduced osteoclast formation and bone loss via CysLTR1 and P2Y12. Mol Med Rep 2018;18:2387-98.
127. Zheng C, Shi X. Cysteinyl leukotriene receptor 1 (cysLT1R) regulates osteoclast differentiation and bone resorption. Artif Cells Nanomed Biotechnol 2018;46:S64-70.
128. Lee NK, Choi YG, Baik JY, et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 2005;106:852-9.
129. Luo X, Fu Y, Loza AJ, et al. Stromal-initiated changes in the bone promote metastatic niche development. Cell Rep 2016;14:82-92.
130. Wei J, Chen S, Huang C, et al. The cysteinyl leukotriene receptor 1 (CysLT1R) antagonist montelukast suppresses matrix metalloproteinase-13 expression induced by lipopolysaccharide. Int Immunopharmacol 2018;55:193-7.
131. Boehmler AM, Drost A, Jaggy L, et al. The CysLT1 ligand leukotriene D4 supports alpha4beta1- and alpha5beta1-mediated adhesion and proliferation of CD34+ hematopoietic progenitor cells. J Immunol 2009;182:6789-98.
132. Drost AC, Seitz G, Boehmler A, et al. The G protein-coupled receptor CysLT1 mediates chemokine-like effects and prolongs survival in chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:665-73.
133. Finetti F, Travelli C, Ercoli J, Colombo G, Buoso E, Trabalzini L. Prostaglandin E2 and cancer: insight into tumor progression and immunity. Biology (Basel) 2020;9:434.
134. Montezuma MAP, Fonseca FP, Benites BM, et al. COX-2 as a determinant of lower disease-free survival for patients affected by ameloblastoma. Pathol Res Pract 2018;214:907-13.
135. Sun H, Zhang X, Sun D, et al. COX-2 expression in ovarian cancer: an updated meta-analysis. Oncotarget 2017;8:88152-62.
136. Esbona K, Yi Y, Saha S, et al. The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients. Am J Pathol 2018;188:559-73.
137. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;379:1591-601.
138. Charalambous MP, Maihöfner C, Bhambra U, Lightfoot T, Gooderham NJ. Colorectal Cancer Study Group. Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells. Br J Cancer 2003;88:1598-604.
139. Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009;17:55-67.
140. Cui Y, Shu XO, Li HL, et al. Prospective study of urinary prostaglandin E2 metabolite and pancreatic cancer risk. Int J Cancer 2017;141:2423-9.
141. Miao J, Lu X, Hu Y, et al. Prostaglandin E(2) and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment. Oncotarget 2017;8:89802-10.
142. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 2002;62:403-8.
143. Myung SJ, Rerko RM, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A 2006;103:12098-102.
144. Yan M, Myung SJ, Fink SP, et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A 2009;106:9409-13.
145. Nakanishi M, Menoret A, Tanaka T, et al. Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity. Cancer Prev Res (Phila) 2011;4:1198-208.
146. Howe LR, Subbaramaiah K, Kent CV, et al. Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis. Prostaglandins Other Lipid Mediat 2013;106:99-105.
147. O'Callaghan G, Houston A. Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? Br J Pharmacol 2015;172:5239-50.
148. Uluçkan O, Eagleton MC, Floyd DH, et al. APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. J Cell Biochem 2008;104:1311-23.
149. Inada M, Takita M, Yokoyama S, et al. Direct Melanoma Cell Contact Induces Stromal Cell Autocrine Prostaglandin E2-EP4 Receptor Signaling That Drives Tumor Growth, Angiogenesis, and Metastasis. J Biol Chem 2015;290:29781-93.
150. Hiraga T, Myoui A, Choi ME, Yoshikawa H, Yoneda T. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res 2006;66:2067-73.
151. Singh B, Berry JA, Shoher A, Lucci A. COX-2 induces IL-11 production in human breast cancer cells. J Surg Res 2006;131:267-75.
152. Singh B, Berry JA, Vincent LE, Lucci A. Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. J Surg Res 2006;134:44-51.
153. Xu S, Zhou W, Ge J, Zhang Z. Prostaglandin E2 receptor EP4 is involved in the cell growth and invasion of prostate cancer via the cAMPPKA/PI3KAkt signaling pathway. Mol Med Rep 2018;17:4702-12.
154. Karavitis J, Zhang M. COX2 regulation of breast cancer bone metastasis. Oncoimmunology 2013;2:e23129.
155. Singh B, Berry JA, Shoher A, Ayers GD, Wei C, Lucci A. COX-2 involvement in breast cancer metastasis to bone. Oncogene 2007;26:3789-96.
156. Watanabe K, Tominari T, Hirata M, et al. Abrogation of prostaglandin E-EP4 signaling in osteoblasts prevents the bone destruction induced by human prostate cancer metastases. Biochem Biophys Res Commun 2016;478:154-61.
157. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2001;91:737-43.
158. Knab LM, Grippo PJ, Bentrem DJ. Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase. World J Gastroenterol 2014;20:10729-39.
159. Yoshimura R, Matsuyama M, Tsuchida K, Kawahito Y, Sano H, Nakatani T. Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. J Urol 2003;170:1994-9.
160. Hoque A, Lippman SM, Wu TT, et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 2005;26:785-91.
161. Matsuyama M, Yoshimura R, Mitsuhashi M, et al. 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. Oncol Rep 2005;14:73-9.
162. Steinhilber D, Fischer AS, Metzner J, et al. 5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis. Front Pharmacol 2010;1:143.
163. Magnusson C, Ehrnström R, Olsen J, Sjölander A. An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinomas correlates with high differentiation. Cancer Res 2007;67:9190-8.
164. Tornhamre S, Stenke L, Granzelius A, et al. Inverse relationship between myeloid maturation and leukotriene C4 synthase expression in normal and leukemic myelopoiesis-consistent overexpression of the enzyme in myeloid cells from patients with chronic myeloid leukemia. Exp Hematol 2003;31:122-30.
165. Ali HEA, Lung PY, Sholl AB, et al. Dysregulated gene expression predicts tumor aggressiveness in African-American prostate cancer patients. Sci Rep 2018;8:16335.
166. Paruchuri S, Hallberg B, Juhas M, Larsson C, Sjölander A. Leukotriene D(4) activates MAPK through a Ras-independent but PKCepsilon-dependent pathway in intestinal epithelial cells. J Cell Sci 2002;115:1883-93.
167. Mezhybovska M, Wikström K, Ohd JF, Sjölander A. The inflammatory mediator leukotriene D4 induces beta-catenin signaling and its association with antiapoptotic Bcl-2 in intestinal epithelial cells. J Biol Chem 2006;281:6776-84.
168. Massoumi R, Nielsen CK, Azemovic D, Sjölander A. Leukotriene D4-induced adhesion of Caco-2 cells is mediated by prostaglandin E2 and upregulation of α2β1-integrin. Exp Cell Res 2003;289:342-51.
169. Salim T, Sand-Dejmek J, Sjölander A. The inflammatory mediator leukotriene D4 induces subcellular β-catenin translocation and migration of colon cancer cells. Exp Cell Res 2014;321:255-66.
170. Chen X, Li N, Wang S, et al. Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. J Natl Cancer Inst 2003;95:1053-61.
171. Zhao S, Yao K, Li D, et al. Inhibition of LTA4H by bestatin in human and mouse colorectal cancer. EBioMedicine 2019;44:361-74.
172. Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE. LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun 2005;335:949-56.
173. Ihara A, Wada K, Yoneda M, Fujisawa N, Takahashi H, Nakajima A. Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci 2007;103:24-32.
174. Kim H, Choi JA, Kim JH. Ras promotes transforming growth factor-β (TGF-β)-induced epithelial-mesenchymal transition via a leukotriene B4 receptor-2-linked cascade in mammary epithelial cells. J Biol Chem 2014;289:22151-60.
175. Tian W, Jiang X, Sung YK, et al. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation. Circulation 2019;140:1409-25.
176. Chheda ZS, Sharma RK, Jala VR, Luster AD, Haribabu B. Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors. J Immunol 2016;197:2016-26.
177. Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008;26:848-55.
178. Jänne PA, Paz-Ares L, Oh Y, et al. Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer. J Thorac Oncol 2014;9:126-31.
179. Tsai MJ, Wu PH, Sheu CC, et al. Cysteinyl leukotriene receptor antagonists decrease cancer risk in asthma patients. Sci Rep 2016;6:23979.
180. Gunning WT, Kramer PM, Steele VE, Pereira MA. Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res 2002;62:4199-201.
181. Nozaki M, Yoshikawa M, Ishitani K, et al. Cysteinyl leukotriene receptor antagonists inhibit tumor metastasis by inhibiting capillary permeability. Keio J Med 2010;59:10-8.
182. Jose MA, Amathi R, Sathyamurthy D, Kumar BN. Chemopreventive effect of montelukast in n-nitroso n-methyl urea induced mammary carcinogenesis in female Sprague-Dawley rats. Indian J Pharmacol 2013;45:286-8.
183. Savari S, Liu M, Zhang Y, Sime W, Sjölander A. CysLT(1)R antagonists inhibit tumor growth in a xenograft model of colon cancer. PLoS One 2013;8:e73466.
184. Satapathy SR, Sjölander A. Cysteinyl leukotriene receptor 1 promotes 5-fluorouracil resistance and resistance-derived stemness in colon cancer cells. Cancer Lett 2020;488:50-62.
185. Tumber A, Morgan HM, Meikle MC, Hill PA. Human breast-cancer cells stimulate the fusion, migration and resorptive activity of osteoclasts in bone explants. Int J Cancer 2001;91:650-3.
186. Poczobutt JM, Nguyen TT, Hanson D, et al. Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment. J Immunol 2016;196:891-901.
188. Fishbein A, Wang W, Yang H, et al. Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression. Proc Natl Acad Sci U S A 2020;117:21576-87.
189. Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O’Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 2001;61:2207-11.
190. Chang J, Bhasin SS, Bielenberg DR, et al. Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin. FASEB J 2019;33:114-25.
191. Filippou PS, Karagiannis GS. Cytokine storm during chemotherapy: a new companion diagnostic emerges? Oncotarget 2020;11:213-5.
192. Gartung A, Yang J, Sukhatme VP, et al. Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor. Proc Natl Acad Sci U S A 2019;116:1698-703.
193. Karagiannis GS, Pastoriza JM, Wang Y, et al. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Sci Transl Med 2017;9:eaan0026.
194. Shaked Y. The pro-tumorigenic host response to cancer therapies. Nat Rev Cancer 2019;19:667-85.
195. Volk-Draper L, Hall K, Griggs C, et al. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res 2014;74:5421-34.
196. Sulciner ML, Serhan CN, Gilligan MM, et al. Resolvins suppress tumor growth and enhance cancer therapy. J Exp Med 2018;215:115-40.
197. Gilligan MM, Gartung A, Sulciner ML, et al. Aspirin-triggered proresolving mediators stimulate resolution in cancer. Proc Natl Acad Sci U S A 2019;116:6292-7.
198. Liu H, Zeng J, Huang W, et al. Colorectal cancer is associated with a deficiency of Lipoxin A(4), an endogenous anti-inflammatory mediator. J Cancer 2019;10:4719-30.
199. Panigrahy D, Edin ML, Lee CR, et al. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest 2012;122:178-91.
200. Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest 2018;128:2657-69.
201. Sulciner ML, Gartung A, Gilligan MM, Serhan CN, Panigrahy D. Targeting lipid mediators in cancer biology. Cancer Metastasis Rev 2018;37:557-72.
202. Ye Y, Scheff NN, Bernabé D, et al. Anti-cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma. Neuropharmacology 2018;139:182-93.
203. Serhan CN. The resolution of inflammation: the devil in the flask and in the details. FASEB J 2011;25:1441-8.
205. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature 2014;510:92-101.
206. Fishbein A, Hammock BD, Serhan CN, Panigrahy D. Carcinogenesis: Failure of resolution of inflammation? Pharmacol Ther 2021;218:107670.
207. Chiang N, Serhan CN, Dahlén SE, et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006;58:463-87.
